Soluble TREM2 regulation of microglial function in Alzheimer disease
可溶性 TREM2 对阿尔茨海默病小胶质细胞功能的调节
基本信息
- 批准号:10432584
- 负责人:
- 金额:$ 43.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-05 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAgeAlzheimer&aposs DiseaseAmericanAmyloid beta-ProteinApoptoticBindingBinding ProteinsBrainCRISPR/Cas technologyCandidate Disease GeneCause of DeathCellsChimeric ProteinsDementiaDepositionDevelopmentDiseaseEngineeringFunctional disorderGeneticHumanImmunologic ReceptorsIntegral Membrane ProteinIntrathecal InjectionsKnockout MiceLipoproteinsMembraneMicrogliaModelingMusPathologyPhagocytosisPhospholipidsPreventionProteinsRegulationRiskRisk FactorsSenile PlaquesSignal TransductionSliceTREM2 geneTYROBP geneTimeUnited StatesVariantbeta amyloid pathologybrain cellcognitive functioncost estimateefficacy evaluationexperimental studygenetic variantgenome wide association studyimprovedmouse modelnovel strategiesnovel therapeuticsprotein aggregationreceptorreceptor bindingtherapy developmenttoolwhole genome
项目摘要
PROJECT SUMMARY
Alzheimer's Disease (AD) is the 6th leading cause of death in the United States and more than 5.8 million
Americans suffer from this disease. This year the estimated cost of AD and other dementias is $305 billion, and
could rise to $1.1 trillion by 2050. The cause of AD remains elusive and is likely multifactorial. The greatest risk
factors are known to be age, genetics, and inheritance. Genome-wide association studies have shown that
variants of TREM2 are associated with two to four times the risk of developing AD. TREM2 is an innate immune
receptor expressed in microglia that has been shown to interact with phospholipids, apoptotic cells, lipoproteins,
and oligomeric forms of amyloid-β (Aβ). This protein has been shown to be required for microglial proliferation,
survival, and phagocytosis of Aβ. TREM2 is a transmembrane protein with no intracellular signaling domains;
signal transduction requires binding to DAP12. Upon microglial activation and clustering, TREM2 is cleaved from
the membrane generating soluble TREM2 (sTREM2). Since both membrane-bound TREM2 and sTREM2
coexist during different stages of AD, it has been difficult to differentiate the extent of which each form
independently contributes to disease pathology. It was recently shown that after intrathecal administration,
sTREM2 binds to microglia, transmitting intracellular signals, promoting survival, improving cognitive function,
and mitigating Aβ pathology; it has been postulated that sTREM2 acts through a putative yet unknown receptor.
In this proposal we will utilize a CRISPR/Cas9 whole genome screen to identify the receptor that binds sTREM2
on microglia and promotes signal transduction. Identified candidate genes will be validated in human microglial
cells and knockout mouse models will be generated to further explore the importance of each in the development
of AD and its pathophysiology. These models will serve as tools that will permit us to identify how sTREM2
modulates microglia independently from membrane-bound TREM2. Such discovery will serve as the basis for
novel therapeutics aimed at modulation of the sTREM2 receptor. sTREM2 has also been shown to bind Aβ
plaques. We will exploit this observation and develop sTREM2-fraction crystallizable(sTREM2-Fc) fusion
proteins that bind Aβ plaques and promote activation of microglia and phagocytosis. The sTREM2-Fc fusion
proteins will be validated using slices of brains from 5XFAD mice that accumulate A plaques typical of AD. We
will also perform intrathecal injections, which will allow us to evaluate the efficacy of sTREM2-Fc in eliminating
plaques and activating microglia. Taken together, these are novel approaches that may help to develop therapies
that enhance clearance and prevention of amyloid-β plaque formation for the treatment of AD.
项目总结
阿尔茨海默病(AD)是美国第六大致死原因,超过580万人
美国人患有这种疾病。今年,AD和其他痴呆症的估计成本为3050亿美元,以及
到2050年可能会上升到1.1万亿美元。阿尔茨海默病的病因仍然难以捉摸,可能是多因素造成的。最大的风险
已知的影响因素有年龄、遗传和遗传。全基因组关联研究表明,
TREM2的变异与AD发病风险的两到四倍有关。TREM2是一种先天免疫
在小胶质细胞中表达的受体,已被证明与磷脂、凋亡细胞、脂蛋白、
和低聚形式的淀粉样蛋白-β(Aβ)。这种蛋白质已被证明是小胶质细胞增殖所必需的,
Aβ的存活和吞噬作用。TREM2是一种跨膜蛋白,不含细胞内信号域;
信号转导需要与DAP12结合。在小胶质细胞激活和聚集时,TREM2被从
产生可溶性TREM2(STREM2)的膜。由于膜结合TREM2和sTREM2
在AD的不同阶段共存,很难区分每种形式的程度
独立为疾病病理学做出贡献。最近有研究表明,鞘内给药后,
STREM2与小胶质细胞结合,传递细胞内信号,促进生存,改善认知功能,
和减轻β的病理;据推测,sTREM2通过一个假定的但未知的受体发挥作用。
在这项提案中,我们将利用CRISPR/Cas9全基因组筛选来鉴定与sTREM2结合的受体
并促进信号转导。已确定的候选基因将在人类小胶质细胞中得到验证
将生成细胞和基因敲除小鼠模型,以进一步探讨每种模型在发育中的重要性
阿尔茨海默病及其病理生理学。这些模型将作为工具,使我们能够确定sTREM2如何
独立于膜结合的TREM2调节小胶质细胞。这样的发现将成为
旨在调节sTREM2受体的新疗法。STREM2也被证明与β结合
斑块。我们将利用这一观察结果,开发sTREM2组分可结晶(sTREM2-FC)融合
结合Aβ斑块并促进小胶质细胞激活和吞噬的蛋白质。STREM2-Fc融合
蛋白质将使用5XFAD小鼠的大脑切片进行验证,这些小鼠积累了AD典型的A斑块。我们
还将进行鞘内注射,这将使我们能够评估sTREM2-FC在消除
斑块和激活的小胶质细胞。总而言之,这些都是可能有助于开发治疗方法的新方法
增强清除和防止淀粉样蛋白-β斑块形成用于治疗AD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARCO COLONNA其他文献
MARCO COLONNA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARCO COLONNA', 18)}}的其他基金
Mucosal Immune Defense Mechanisms of the Urinary Bladder
膀胱粘膜免疫防御机制
- 批准号:
10587639 - 财政年份:2023
- 资助金额:
$ 43.06万 - 项目类别:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
多胺对稳态和结肠炎临床前模型中 ILC3 功能的影响
- 批准号:
10528082 - 财政年份:2022
- 资助金额:
$ 43.06万 - 项目类别:
The protein tyrosine kinase SYK drives innate immune responses against Alzheimer's Disease
蛋白质酪氨酸激酶 SYK 驱动针对阿尔茨海默病的先天免疫反应
- 批准号:
10674689 - 财政年份:2022
- 资助金额:
$ 43.06万 - 项目类别:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
多胺对稳态和结肠炎临床前模型中 ILC3 功能的影响
- 批准号:
10623342 - 财政年份:2022
- 资助金额:
$ 43.06万 - 项目类别:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
CNS 边界 B 细胞在稳态、衰老和自身免疫中的个体发育生态位
- 批准号:
10446266 - 财政年份:2022
- 资助金额:
$ 43.06万 - 项目类别:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
CNS 边界 B 细胞在稳态、衰老和自身免疫中的个体发育生态位
- 批准号:
10557870 - 财政年份:2022
- 资助金额:
$ 43.06万 - 项目类别:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
艰难梭菌的微生物群依赖性控制:乙酸盐和 IL-22 结合蛋白的作用
- 批准号:
10321553 - 财政年份:2021
- 资助金额:
$ 43.06万 - 项目类别:
Targeting TREM2 to boost anti-cancer therapy
靶向 TREM2 促进抗癌治疗
- 批准号:
10477296 - 财政年份:2021
- 资助金额:
$ 43.06万 - 项目类别:
Targeting TREM2 to boost anti-cancer therapy
靶向 TREM2 促进抗癌治疗
- 批准号:
10279674 - 财政年份:2021
- 资助金额:
$ 43.06万 - 项目类别:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
艰难梭菌的微生物群依赖性控制:乙酸盐和 IL-22 结合蛋白的作用
- 批准号:
10539270 - 财政年份:2021
- 资助金额:
$ 43.06万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Fellowship
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 43.06万 - 项目类别:
Directed Grant














{{item.name}}会员




